Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.

Join us as we dived into:

• The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd
• Insights on the efficacy of teclistamab in early relapse refractory settings, including updates from the MajesTEC-3 and MajesTEC-9 studies.
• The promising data around talquetamab from the MonumenTAL-3 study, highlighting its significant progression-free survival (PFS) improvement.
• An overview of mezigdomide, a new immunomodulatory agent, and its impact on treatment strategies for anti-CD38 and lenalidomide-refractory patients.

We emphasized the importance of managing side effects and optimizing treatment sequences to ensure our patients can stay on these innovative therapies longer and safely.

Tune in for an informative discussion packed with the latest research and clinical insights in the world of oncology!

Listen to us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.

Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.

Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.

Topics Covered:

• Current treatment options for relapsed multiple myeloma

• Insights from the MajesTEC-3 and MajesTEC-9 studies

• The role of bispecific antibodies and CAR-T therapies

• Managing side effects and patient care strategies

• The importance of community and academic partnerships

Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Tune in now and stay informed about the latest in oncology!

#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs,#OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.

We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.

Key topics covered in this episode included:

• The role of next-generation sequencing (NGS) in guiding treatment options
• Choosing between dual checkpoint inhibitors and IO-TKI combinations
• Managing side effects associated with various treatment regimens
• Sequencing treatment options for patients who progress after initial therapy
• Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms!

#KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI,#OncologyBrothers

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.

In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space:

• PROTEUS: trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm.
• TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance.
• CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study.
• EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up.
• POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population.
• LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice.

#GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer,#RenalCellCarcinoma, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Nina Sanford, a GI radiation oncologist from UT Southwestern, to discuss a critical topic in cancer treatment: when to hold and not to hold systemic therapy during radiation and for how long.

Join us as we explore:

• The framework for balancing systemic therapy with different types of radiation, including SBRT, palliative, and conventional radiation.
• Insights on managing cytotoxic chemotherapy, immunotherapy, TKIs, and targeted therapies in conjunction with radiation.
• The importance of individualized treatment plans and the evolving data around various drug classes, including BRAF inhibitors, PARP inhibitors, and anti-HER2 therapies.
• Practical recommendations for community oncologists navigating these complex decisions.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to check out Dr. Sanford's teaching video for more in-depth information!

#RadiationOncology, #SystemicTherapy, #SBRT,#MultidisciplinaryCare, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies.

We discussed key studies:

• EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes.
• FIGHT-302 in Cholangiocarcinoma: The potential of FGFR inhibitors in frontline settings and the challenges of biomarker testing.
• CIRCULATE Update: The role of ctDNA in stage 2 colon cancer and how it influences treatment decisions.
• MATTERHORN Update: Benefits of perioperative chemotherapy and the importance of maintaining treatment regimens for better patient outcomes.

We also touched on the evolving landscape of GI malignancies and the significance of multidisciplinary approaches in treatment planning.

Tune in for an informative discussion that aims to enhance your understanding of the latest advancements in oncology and their practical applications in the clinic.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

⁠X/Twitter: https://twitter.com/oncbrothers

⁠Instagram: https://www.instagram.com/oncbrothers

Website: https://oncbrothers.com/

Don't forget to subscribe for more updates on treatment algorithms, challenging cases, and conference highlights!

#ASCO2026, #GIOncology, #ctDNA, #FGFRinhibitor, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.

We discussed:

• The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients.
• The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib.
• The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors.
• Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice.
• The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment!
#PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the key highlights from ASCO 2026, focusing on groundbreaking studies in head and neck cancer and sarcoma.

Join us as we discuss:

• Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers?
• Amivantamab in Head and Neck Cancer: Insights from the OrigAMI4 study, showcasing the efficacy of amivantamab in refractory settings, with an impressive overall response rate of 47%.
• SARC041: A look at abemaciclib as a treatment for de-differentiated liposarcoma, highlighting significant improvements in progression-free survival.
• Gastrointestinal Stromal Tumors (GIST): The PEAK trial results, explored the combination of bezuclastinib and sunitinib after progression on imatinib, showing promising outcomes.

We are thrilled to have Dr. Ari Rosenberg from the University of Chicago and Dr. Sam Armstrong from Indiana University join us to share their expertise and insights on these important studies.

Listen us on:Spotify:

https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11

Apple Podcast:

https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Tune in for an informative discussion that sheds light on the latest advancements in oncology! Don’t forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers.

#ASCO2026, #HeadAndNeckCancer, #Sarcoma, #GIST, #OncologyBrothers